A UK-led trial has found that combining a chemotherapy drug with hormone treatment extended the lives of men with advanced prostate cancer.
The drug, called docetaxel, is typically only offered if standard hormone treatment has failed. But these findings, that will be presented at the American Society of Clinical Oncology (ASCO) conference show treating patients whose cancer has already spread earlier extended survival by almost two years.
Experts say the results provide sufficient evidence to suggest that the treatment should be offered to newly diagnosed men whose disease has already spread.
In the study of 2,962 men, those who received docetaxel plus standard hormone therapy at the start of their treatment lived an average of 10 months longer than those who received only hormone treatment.
For patients whose cancer had already spread beyond the pelvis, the average increase in life expectancy was 22 months.
The results form part of the STAMPEDE trial (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy), the largest trial of its kind for men with prostate cancer.
More detail at Cancer Research UK